# Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT00377104** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Contiguous Stage II Small Lymphocytic Lymphoma
- Noncontiguous Stage II Small Lymphocytic Lymphoma
- Stage I Chronic Lymphocytic Leukemia
- Stage I Small Lymphocytic Lymphoma
- Stage II Chronic Lymphocytic Leukemia
- Stage III Chronic Lymphocytic Leukemia
- Stage III Small Lymphocytic Lymphoma
- Stage IV Chronic Lymphocytic Leukemia
- Stage IV Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** alvocidib
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00377104
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2012-11
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377104, "Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00377104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*